Harrow Health, Inc.
HROW · NASDAQ
Bulios Fair Price
$44.09
27.9% upside
Current Price
$34.48
According to Bulios Fair Price, HROW is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Harrow Health, Inc. is a pharmaceutical company primarily focused on providing affordable and innovative drugs and healthcare products. The company specializes in the development and commercialization of pharmaceuticals and medical devices in the fields of ophthalmology, dermatology, and neurology. Their portfolio includes a wide range of therapeutic products, including generics, branded drugs, and medical devices, aimed at treating various health conditions and diseases. Harrow Health, Inc. focuses on providing affordable and quality medications for patients and strengthening its position in the pharmaceuticals and healthcare products market.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mark L. Baum
Employees
373
Headquarters
Nashville
Upcoming events
Earnings
Upcoming earnings report